Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to announce any potential takeover. The company received its...
Big Pharma firms like AbbVie are partnering with delivery device makers to guard against biosimilar competition according to Unilife CEO, Alan Shortall.
Unilife says its 15 year-wearable injector supply deal with Sanofi is “unprecendented” and could result in over $1bn of sales annually for the delivery device maker.
Unilife has invested in manufacturing capacity for its drug delivery devices ahead of schedule to support the accelerated commercial launch date of its customers' products.
Unilife says it is confident future revenue from current contracts could total $1bn and is scaling up manufacturing capacities despite no product sales in the third quarter.
Injectable device manufacturer Unilife has announced a contract with a pharmaceutical multinational for the use of its Ocu-ject eye syringe, marking its fifth major contract in four months.
